SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
FRA:1SXP - Deutsche Boerse Ag - DE000A3ENQ51 - Common Stock - Currency: EUR
Taking everything into account, 1SXP scores 5 out of 10 in our fundamental rating. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. While showing a medium growth rate, 1SXP is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
In the past year 1SXP had a positive cash flow from operations.
In the past 5 years 1SXP has always been profitable.
1SXP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of 1SXP (9.93%) is better than 100.00% of its industry peers.
The Return On Equity of 1SXP (17.64%) is better than 100.00% of its industry peers.
The Return On Invested Capital of 1SXP (14.25%) is better than 94.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1SXP is significantly above the industry average of 6.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.93% | ||
| ROE | 17.64% | ||
| ROIC | 14.25% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP's Profit Margin of 15.17% is amongst the best of the industry. 1SXP outperforms 84.21% of its industry peers.
1SXP's Profit Margin has been stable in the last couple of years.
Looking at the Operating Margin, with a value of 18.95%, 1SXP is in the better half of the industry, outperforming 78.95% of the companies in the same industry.
In the last couple of years the Operating Margin of 1SXP has grown nicely.
1SXP has a Gross Margin (32.90%) which is comparable to the rest of the industry.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 18.95% | ||
| PM (TTM) | 15.17% | ||
| GM | 32.9% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1SXP is creating value.
1SXP has about the same amout of shares outstanding than it did 1 year ago.
Compared to 1 year ago, 1SXP has a worse debt to assets ratio.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.33. This is a very positive value and a sign of high solvency as it would only need 1.33 years to pay back of all of its debts.
1SXP has a Debt to FCF ratio of 1.33. This is amongst the best in the industry. 1SXP outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.10. This is amongst the best in the industry. 1SXP outperforms 89.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.33 | ||
| Altman-Z | N/A |
ROIC/WACC1.88
WACC7.58%
2.3 Liquidity
A Current Ratio of 1.43 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a Current ratio of 1.43. This is in the lower half of the industry: 1SXP underperforms 68.42% of its industry peers.
A Quick Ratio of 1.07 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a worse Quick ratio (1.07) than 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.07 |
3. Growth
3.1 Past
1SXP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.93%.
1SXP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.04% yearly.
The Revenue for 1SXP has decreased by -28.74% in the past year. This is quite bad
1SXP shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.84% yearly.
EPS 1Y (TTM)-32.93%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%7.95%
3.2 Future
1SXP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.91% yearly.
1SXP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.19% yearly.
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y12.91%
Revenue Next Year5.25%
Revenue Next 2Y8.4%
Revenue Next 3Y9.21%
Revenue Next 5Y9.19%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 26.53 indicates a quite expensive valuation of 1SXP.
1SXP's Price/Earnings ratio is a bit cheaper when compared to the industry. 1SXP is cheaper than 73.68% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, 1SXP is valued at the same level.
With a Price/Forward Earnings ratio of 20.75, 1SXP is valued on the expensive side.
Compared to the rest of the industry, the Price/Forward Earnings ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 63.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, 1SXP is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.53 | ||
| Fwd PE | 20.75 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP is on the same level as its industry peers.
1SXP's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. 1SXP is more expensive than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 58.7 | ||
| EV/EBITDA | 15.46 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of 1SXP may justify a higher PE ratio.
A more expensive valuation may be justified as 1SXP's earnings are expected to grow with 13.40% in the coming years.
PEG (NY)5.37
PEG (5Y)N/A
EPS Next 2Y12.5%
EPS Next 3Y13.4%
5. Dividend
5.1 Amount
1SXP has a yearly dividend return of 0.60%, which is pretty low.
1SXP's Dividend Yield is a higher than the industry average which is at 0.71.
With a Dividend Yield of 0.60, 1SXP pays less dividend than the S&P500 average, which is at 2.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.33% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.33%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
FRA:1SXP (7/11/2025, 7:00:00 PM)
26
-0.7 (-2.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.43%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.92B
Analysts76.84
Price Target30.64 (17.85%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.6% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.47%
Min EPS beat(2)-14.42%
Max EPS beat(2)5.48%
EPS beat(4)2
Avg EPS beat(4)7.72%
Min EPS beat(4)-14.42%
Max EPS beat(4)50.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-5.31%
Max Revenue beat(2)1.75%
Revenue beat(4)2
Avg Revenue beat(4)1.13%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)11.1%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.51%
PT rev (3m)5.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.26%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.38%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.53 | ||
| Fwd PE | 20.75 | ||
| P/S | 4.03 | ||
| P/FCF | 58.7 | ||
| P/OCF | 18.98 | ||
| P/B | 4.68 | ||
| P/tB | 4.86 | ||
| EV/EBITDA | 15.46 |
EPS(TTM)0.98
EY3.77%
EPS(NY)1.25
Fwd EY4.82%
FCF(TTM)0.44
FCFY1.7%
OCF(TTM)1.37
OCFY5.27%
SpS6.46
BVpS5.56
TBVpS5.35
PEG (NY)5.37
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.93% | ||
| ROE | 17.64% | ||
| ROCE | 17.43% | ||
| ROIC | 14.25% | ||
| ROICexc | 14.71% | ||
| ROICexgc | 15.16% | ||
| OM | 18.95% | ||
| PM (TTM) | 15.17% | ||
| GM | 32.9% | ||
| FCFM | 6.86% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexcg growth 3Y-8.59%
ROICexcg growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score4
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 1.33 | ||
| Debt/EBITDA | 0.32 | ||
| Cap/Depr | 193.54% | ||
| Cap/Sales | 14.35% | ||
| Interest Coverage | 12.84 | ||
| Cash Conversion | 80.44% | ||
| Profit Quality | 45.2% | ||
| Current Ratio | 1.43 | ||
| Quick Ratio | 1.07 | ||
| Altman-Z | N/A |
F-Score4
WACC7.58%
ROIC/WACC1.88
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-32.93%
EPS 3Y14.04%
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next Y4.94%
EPS Next 2Y12.5%
EPS Next 3Y13.4%
EPS Next 5Y12.91%
Revenue 1Y (TTM)-28.74%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%7.95%
Revenue Next Year5.25%
Revenue Next 2Y8.4%
Revenue Next 3Y9.21%
Revenue Next 5Y9.19%
EBIT growth 1Y-27.36%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year39.55%
EBIT Next 3Y25.42%
EBIT Next 5Y19.41%
FCF growth 1Y1205.97%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y24.04%
OCF growth 3Y19.45%
OCF growth 5YN/A